Conclusions
The current study demonstrated that sevoflurane upregulated GLUT1, MPC1,
and GLUD1 expressions of ovarian cancer cells, while propofol
downregulated the expressions of these molecules. These regulations by
sevoflurane or propofol on ovarian cancer cells led to different
metabolic features. The upregulated GLUT1 expression and, in turn,
increased glucose uptake after sevoflurane exposure resulted in a
decreased expression of PEDF. In opposite, an increased expression of
PEDF was identified after propofol treatment. Furthermore, in contrast
to propofol, sevoflurane upregulated Erk1/2 pathway, HIF-1α, CXCL12 and
CXCR4 expressions through PEDF inhibition per se . In summary, the
profiling alterations of molecular and metabolic modulations found in
the present study indicate the pro- and anti-tumour properties of
sevoflurane and propofol, respectively. The translational value of these
is subjected to study further in clinical settings.